Background: Early access program (formerly cohort Temporary Authorization for Use) was granted for trastuzumab deruxtecan (T‐DXd) in France based on DESTINY‐Breast01 trial which demonstrated its efficacy and safety in HER2‐positive metastatic/unresectable breast cancer after ≥2 anti‐HER2...
ABSTRACTTrastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerS. Modi, W. Jacot, T. Yamashita, J. Sohn, M. Vidal, E. Tokunaga, J. Tsurutani, N.T. Ueno, A. Prat, Y.S. Chae, K.S. Lee, N. Niikura, Y.H. Park, B. Xu, X. Wang, M. Gil‑Gil, W. Li...
TPS508#Background:Valemetostat tosylate (valemetostat), a novel and selective dual inhibitor of enhancer of zeste homolog (EZH)2 and EZH1, has demonstrated clinical efficacy and tolerability in multiple hematologic cancers (200 mg orally [PO] once daily [QD]). EZH2 inhibition by valemeto...
2022年8月美国食品药品监督管理局(FDA)批准抗体偶联药物T-DXd(Trastuzumab Deruxtecan,曲妥珠单抗Deruxtecan)用于治疗晚期HER2低表达乳腺癌,这是目前全球首个HER2低表达乳腺癌靶向疗法。 T-DXd的此次获批或将改写乳腺癌的临床分型和治疗标准,开启“HER2低表达”乳腺癌的精准治疗时代。 为何T-DXd能表现的如此突出呢?
编者按:近日,欧盟委员会批准fam-trastuzumab deruxtecan-nxki(T-DXd; Enhertu)作为既往已接受过曲妥珠单抗为基础的方案的晚期HER2阳性胃或胃食管交界处(GEJ)腺癌患者的单药治疗。 T-DXd是欧盟首个批准的HER2靶向治疗,用于以曲妥珠单抗为...
德曲妥珠单抗(Trastuzumab deruxtecan)优赫得的耐药及药物相互作用,德曲妥珠单抗(Trastuzumab deruxtecan)是一种针对肿瘤细胞具有特异性识别和杀伤作用的单抗药物,主要适应症是用于治疗HER2阳性的乳腺癌、胃癌等肿瘤。该药品在临床试验中表现出色,疗效显著、安全性高,极大地提高了患者的生活质量。
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast CancerMore about fam-trastuzumab deruxtecan Check interactions Compare alternatives Reviews (27) Side effects Dosage information During pregnancy Drug class: HER2 inhibitors En español Patient resources Fam-trastuzumab deruxtecan-nxki ...
Trastuzumab deruxtecan (Enhertu; AstraZeneca, Daiichi Sankyo) demonstrated clinically meaningful tumor responses in previously treated patients with human epidermal growth factor receptor 2 mutant (HER2m) unresectable and/or metastatic non-squamous non–small cell lung cancer (NSCLC), ...
3.Modi Shanu,Jacot William,Yamashita Toshinari et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.[J] .N Engl J Med, 2022, undefined: undefined. 4.NCCN Guideline Breast Cancer 2022.V4 5.https://www.asco.org/practice-patients/guidelines/breast-cancer#/9781 ...
德曲妥珠单抗(Trastuzumab deruxtecan)优赫得的使用说明 德喜曲妥珠单抗生产厂家:英国阿斯利康功能主治:靶向HER2的抗体和拓扑异构酶抑制剂的药物偶联物。用法用量:用法用量 1.乳腺癌患者的推荐剂量为5.4 mg/kg,每3周(21天周期)静脉输注一次,直至疾病进展或出现不可耐受的毒性。 2.肺癌患者的推荐剂量为5.4 mg/kg,...